Stock BOLD BOUNDLESS BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Boundless Bio, Inc.

Equities

BOLD

US10170A1007

Market Closed - Nasdaq
Other stock markets
 01:30:00 13/06/2024 am IST 		5-day change 1st Jan Change
7.72 USD -16.27% Intraday chart for Boundless Bio, Inc. -13.84% 0.00%
22/04 Guggenheim Starts Coverage on Boundless Bio With Buy Rating, $24 Price Target MT
22/04 Piper Sandler Starts Audentes Therapeutics With Overweight Rating, $20 Price Target MT

Evolution of the average Target Price on Boundless Bio, Inc.

Price target over the last 5 years

History of analyst recommendation changes

f1.oTDewKeKxTI2Is3IfFFVm7tT3lz__2EatzmhaqdRXcE.mAeBr8HJ8mtecYGbBDI34dYar2THhgx5gHLOB_Q-EaaYdomT476oSm5qiA~b1c059f355af597cb01fc6c658e291f9

Analyst Recommendations on Boundless Bio, Inc.

Guggenheim Starts Coverage on Boundless Bio With Buy Rating, $24 Price Target MT
Piper Sandler Starts Audentes Therapeutics With Overweight Rating, $20 Price Target MT
Boundless Bio Insider Bought Shares Worth $3,200,000, According to a Recent SEC Filing MT
Boundless Bio Insider Bought Shares Worth $3,200,000, According to a Recent SEC Filing MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
7.72 USD
Average target price
23 USD
Spread / Average Target
+197.93%
High Price Target
25 USD
Spread / Highest target
+223.83%
Low Price Target
20 USD
Spread / Lowest Target
+159.07%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Boundless Bio, Inc.

Piper Sandler
Guggenheim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. BOLD Stock
  4. Consensus Boundless Bio, Inc.